Team Members

Principal Investigator

greg thurber

Dr. Greg Thurber

Associate Professor of Chemical Engineering
Associate Professor of Biomedical Engineering

gthurber AT

Harvard Medical School, Massachusetts General Hospital: T32 Traineeship in Molecular Imaging
Ph.D, Massachusetts Institute of Technology
BS, Pennsylvania State University

Graduate Students

ceila shujun dong

Celia Shujun Dong

Antibody-drug conjugates can stimulate immune system via interaction between FcRs and Fcs. Previous research has proved that the payloads (drug) also have the potential to encourage immune response. I’m making a head to head comparison of different payloads on their abilities to stimulate dendritic cells which, due to their antigen-presenting mechanism, are important in the entire process of immune response. I’m also using pharmacokinetic model and will be using a hybrid angent-based model to do some simulation.

Co-advised by Prof. Jennifer Linderman

haolong huang

Haolong Huang

I am working on peptide engineering.

jane kwon

Hyeyoung “Jane” Kwon

Antibody-drug conjugates (ADC) have the advantage of targeting tumor cells and directly delivering payloads (drugs) into them. However, we often confront the challenges of the uneven distribution of ADC and less efficient penetration. Analyzing the transport properties of ADC as well as understanding its interaction with the immune system is significant for improving the drug efficacy. I am working on the characterization of antibody-drug conjugates for enhanced distribution in the cancer cells and immune responses.

Melissa Calopiz

Using agent-based modeling, I will be studying the relationship between antibody drug conjugates and immune cells for cancer therapies. This model will be able to predict the impact of ADC drug distribution in tumors and capture improved responses with increased tissue penetration.

Co-advised by Prof. Jennifer Linderman

baron rubahamya

Baron Rubahamya

A number of antibody-drug conjugates (ADCs) have been approved by the FDA and more are in early clinical trials and preclinical development. An important aspect about ADCs is their ability to combine the potency of small molecules and the targeting of antibodies. I am studying the characteristics of ADCs and the factors within the tumor microenvironment that affect and influence their efficacy as anti-cancer agents.

Tiexin wang

Tiexin Wang

I am working on protein engineering and antibody drug conjugates.

Co-advised by Prof. Peter Tessier

jiakun guan

Jiakun Guan

I am working on the protease-activated T-Cell Engager that cross-link tumor cells with T-Cells via a bispecific protein therapeutic. A working system pharmacology model will be developed to capture the systemic distribution of it and to validate uptake and distribution in a mouse xenograft model.

Namir Khalasawi

I am working on designing immunomodulatory antibody therapies, including T-cell agonists, T-cell engagers, and immunocytokines. These molecules have shown promise for treating a number of diseases, including cancer and autoimmunity.

Co-advised by Prof. Peter Tessier

Ananya Burli

Exploration of Krogh cylinder model refinement with payload recycling.

Dong Jun Koo

The recent successes of ADCs in the clinic have underscored the importance of tailoring ADC drug properties for specific targets. However, the complexity of these molecules poses a challenge in thoroughly screening all potential combinations of protein, linker, and payload during development. My work focuses on applying fundamental drug transport principles to efficiently design ADCs for maximum efficacy at clinically tolerated doses.

Juan Jimenez

Modeling drug uptake and distribution across the BBB (Blood-Brain Barrier), with applications for treatment of cancer and neurodegenerative diseases. 

Co-advised by Prof. Peter Tessier

Alaa Mwfay

I’m working on high-throughput tools for biodistribution analysis and PK modeling.

Co-advised by Prof. Alexandra S. Piotrowski-Daspit

Current Undergraduates

Jordan Vinh
Andrew Philippart
Sophia Freytag

Undergraduate Alumni

Matt Ratanapanichkich

Sophie Gable, (2019-2020)
Hannah Levy, (2019-2020)
Rohan Perisetla, (2019)
Zhongyuan Zhang, (2016-2017)
Nadia Auchus, (2015-2016)
Hans Guo, (2015-2016)
Jianshan Liao, (2014-2016)
Dyanne Neoh, (2014-2015)
Matt Riley, (2013-2014)
Allison DuRoss, (2012-2014)

Matthew Proefke

Darby McKernan, (2019-2020)
Rahul Gopinath, (2018-2020)
Neelay Patel, (2019)
Andrew Min, (2016-2018)
Daniel Tresnak, (2015-2017)
Nik Christodolu, (2015-2016)
Victoria Eniola, (2016)
Liz Goulston, (2015-2016)
Aaron Priluck, (2013-2015)
Rachel Blaisdell, (2014)

Graduate Alumni

Dr. Anna Kopp, Ph.D 2023 now at Amgen

Dr. Marshall Case, Ph.D 2023 now at Manifold Bio

Dr. Reginald Evans, Ph.D 2022

Dr. Ian Nessler, Ph.D 2022, now at AbbVie

Dr. Bruna Menezes/Scheuher, Ph.D 2020, now at Applied Biomath

Dr. Eshita Khera, Ph.D 2020, now at Novartis

Yinuo Chen, Masters 2020

Dr. Lydia Atangcho, Ph.D 2020, now at BCG

Dr. Tejas Navaratna, Ph.D 2020, now a post-doc at UCSB

Dr. Mukesh Mahajan, Postdoctoral researcher (2019)

Dr. Cornelius Cilliers, Ph.D 2018, now at Mirati Therapeutics

Dr. Sumit Bhatnagar, Ph.D 2018, now at AbbVie

Dr. Liang Zhang, Ph.D 2017, now at AbbVie

Emily Deschenes, Masters 2016

Dr. Kirti Dhingra, Postdoctoral Fellow (2013-2014)